Home » Topics » BioWorld Science

BioWorld Science
RSS

Sorrento Therapeutics and Mount Sinai partner on antibody cocktail for COVID-19

May 13, 2020

Integrated herpesvirus 6 is pre-eclampsia risk factor

May 13, 2020

Genfit reports phase III interim data on elafibranor in NASH

May 12, 2020

Phase III study of Sarclisa in relapsed multiple myeloma meets primary endpoint

May 12, 2020

FDA clears IND for phase Ib/IIa study of HST-001 for androgenic alopecia

May 12, 2020

Phase I study of BRD4 inhibitor SYHA-1801 begins for advanced solid tumors

May 12, 2020

Ustekinumab efficacy demonstrated in pediatric Crohn's disease patients

May 12, 2020

Enrollment underway for first-in-human study of BRAF inhibitor ABM-1310 in advanced solid tumors

May 12, 2020

Canakinumab studied in phase III for CRS in patients with COVID-19-induced pneumonia

May 12, 2020

Boehringer Ingelheim studies BI-456906 for type 2 diabetes in new phase II trial

May 12, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...